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ABSTRACT
Introduction: Venous thromboembolism (VTE) is a multifactorial genetic disorder 
that occurs in approximately one in a thousand adults per year. Because there is 
no laboratory test or clinical marker useful for predicting which patients with Fabry 
disease may develop thrombotic events, this study aimed to determine whether there 
is a hereditary predisposition to hypercoagulation in these patients.
Methods: The prevalence of p.R506Q mutation in the factor V gene and of c.G20210A 
mutation in Factor II (prothrombin) gene was evaluated in 39 patients with Fabry 
disease from Southern Brazil and correlated with clinical findings. The DNA analysis 
was performed by real-time polymerase chain reaction on genomic DNA using 
TaqMan probes.
Results: In this group of patients, the frequency of mutation in the prothrombin gene 
was 1.28%, whereas no patient showed mutation in the factor V gene; additionally, there 
was no correlation between these mutations and the incidence of thrombotic events.
Conclusion: Hereditary thrombophilia due to mutations in factor V and prothrombin 
genes does not seem to be related to thrombotic events in Fabry patients in our 
cohort, although studies in larger cohorts and the inclusion of additional factors may 
be required to determine if a correlation exists.
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Venous thromboembolism (VTE) is a multifactorial disorder whose etiology 
involves the interaction of genetic and/or acquired risk factors that affect proteins 
of the coagulation system. Among the genetic factors, mutations in the factor 
V and prothrombin genes are the two main causes of hereditary thrombosis1,2. 
The p.R506Q mutation, also known as Factor V Leiden (FVL) mutation, refers 
to an alteration in the factor V gene that could result in activated protein C 
(APC) resistance and subsequently in the imbalance between hemostasis and 
thrombosis1-4. The prothrombin c.G20210A mutation is a point mutation in the 
3’-untranslated region of the factor II gene, which can increase the synthesis 
of prothrombin and thereby increase its concentration5. In a meta-analysis 
Kim et al, showed that these two gene mutations, alone or in combination 
with other risk factors can increase the occurrence / recurrence of VTE6.
Fabry disease (FD) is an X-linked disorder of glycosphingolipids that is 
caused by mutations in the GLA gene leading to a deficiency of α-galactosidase 
A (GLA) (EC 3.2.1.22) and is associated with dysfunctions of many cell types. 
As a result, patients have a markedly increased risk of developing small-fiber 
peripheral neuropathy, stroke, myriad cardiac manifestations, and chronic renal 
disease. Dysfunction of cerebrovascular circulation in FD has been shown in 
a number of studies using imaging end-points such as cerebral perfusion by 
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positron emission tomography and arterial spin tagging 
using MRI7-9. FD has historically been considered rare, 
with an incidence of one in 40,000 to 117,000 male 
births10; however, a recent newborn screening study 
(which did not include female subjects) demonstrated 
that up to one in 3,100 boys are affected11. Virtually 
all complications of FD are non-specific in nature and 
clinically indistinguishable from similar abnormalities 
that occur in the context of more common disorders 
in the general population. However, a high incidence 
of thrombotic events in FD has been postulated12,13. 
We therefore focused our research on the analysis 
of mutations in coagulation factors which may also 
be involved with such complications by changing the 
state of hemostasis.
FVL heterozygosity is present in around one in 
20 people, and thus the expected concurrence of FVL 
and FD is from 1:62,000 to 1:2,340,000 male patients. 
This combination is comparatively underreported 
in the literature, with only three papers referring to 
human cases and a single mouse model examining 
FVL homozygosity concurrent with FD14-17. Each of 
these studies highlighted the considerable stroke 
risk associated with this genetic combination. One 
theoretical mechanism for this pathological association 
is through the accumulation of globotriaosylceramide 
(GL3) influencing the formation and function of 
antithrombotic lipid rafts, and by doing so altering the 
glycosphingolipid dependent inactivation of factor V 
by APC, a protein that has an important role on the 
regulation of hemostasis. In patients with FD and FVL, 
this would lead to a decreased anticoagulant response 
to APC and a procoagulant state (compared to patients 
with FD but without FVL), leading to cerebral white 
matter lesions and stroke18. Conversely, to date, no 
studies have investigated the association between 
prothrombin mutation and FD, even though the first 
is one of the most frequent mutations predisposing 
to thrombophilia.
METHODS
The study was approved by the local Ethics 
Committee (#08632). The sample comprised 39 patients 
with FD (20 males and 19 females) from 18 families, 
with a mean age of 47.82 years. All the patients were 
followed at the Medical Genetics Service of Hospital 
de Clínicas de Porto Alegre, Brazil (HCPA-SGM), 
which is considered to be the reference center for 
lysosomal disorders in the state of Rio Grande do 
Sul. Patient’s clinical information was obtained from 
medical records.
DNA samples were extracted by the salting out 
technique and were kept frozen. DNA quantitation was 
performed using a spectrophotometer (NanoDrop1000, 
Thermo Fisher Scientific,USA) and then samples 
were diluted to a standard concentration of 20 ng/µL.
For genotyping, real-time polymerase chain 
reaction (PCR) was performed using the TaqMan 
assay, which uses a pair of PCR primers and a 
TaqMan probe containing minor groove binder 
(MGS) at the 3’ end and fluorescent dye (FAM™ or 
VIC) at the 5 ‘end. The two different fluorescent dye 
probes are complementary to either the wild-type 
or the mutant allele. The reaction was performed 
in a 48-well plate using the StepOneTM equipment 
(Applied BiosystemsTM, California,USA). Negative, 
homozygous mutant, heterozygous and homozygous 
wild type standard controls were used in every assay 
in order to allow the clustering of DNA sequences into 
different genotype groups according to the TaqMan 
Genotyper software. Temperature cycles for real-time 
PCR were those pre-established by the manufacturer, 
with an extension temperature of 60 °C.
FV assay (ID _ 11975250 rs6025) contains a 
p.R506Q mutation associated FAM dye-labeled TaqMan 
probe, featuring the amino acid glutamine (Q), while 
VIC dye-labeled TaqMan probe corresponds to the 
normal amino acid, arginine (R). The prothrombin-assay 
(ID _ 87266802-10 rs1799963) with a c.G20210A 
mutation in the VIC probe carries adenine (A) and 
FAM probe carries the codon with guanine (G).
RESULTS
The allele frequency of the c.G20210A mutation 
was 1.28%, corresponding to only one individual 
heterozygous for this mutation (2.56%) and no 
homozygous mutant patients were identified. None 
of the patients were shown to be either heterozygous 
or homozygous for the FVL. The only patient who 
was heterozygous for c.G20210A mutation was a 
48-year-old female with the 30delG mutation in the 
GLA gene. Until now, she had never experienced 
any thrombotic event.
Six patients (15.4%) had at least one thrombotic 
event as stroke or ischemic transient attack. The average 
age of stroke was 53.5 years. From the five patients 
who had an episode of stroke, three were women 
and two were men. Additionally, one man had an 
episode of transient ischemic attack (TIA). Hence, 
in this study 50% of thrombotic events occurred in 
females and 50% in males.
DISCUSSION AND CONCLUSION
Lenders et al. suggested that FVL may increase the 
risk of patients with FD to develop a thromboembolic 
event19. There is controversy whether storage in the 
endothelial cells and the prothrombotic state are 
the origin of arterial damage or whether smooth 
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muscle cell proliferation in the arterial media layer 
is the initiating step in the cascade that leads to FD 
vasculopathy20,21.
Although hereditary thrombophilias are important 
causes of thrombotic events, they were not associated 
with an increased number of these events in our sample 
of patients with FD. The only patient heterozygous 
for the mutation in the prothrombin gene did not 
develop any thrombotic event, while six other patients 
without the analyzed mutations developed stroke 
or TIA. The incidence of hereditary thrombophilia 
varies between different regions and populations 
but is more common in Caucasians. The global 
prevalence of heterozygosity for the mutation in the 
prothrombin gene is 2% on average (1.7 to 2.4%)22, 
while for the prevalence of FVL ranges from 0.45 to 
5.2%22; therefore, we can consider that our findings 
are within the expected range.
Studies in mice demonstrated that the presence 
of FVL homozygosity and GLA deficiency greatly 
increases fibrin deposition and occlusive thrombus 
formation compared with either FVL homozygosity 
or GLA deficiency alone. This observation suggests 
that, under certain circumstances, GLA deficiency 
leads to increased propensity toward spontaneous 
thrombosis15. However, heterozygosity for FVL does 
not appear to increase the risk of arterial stroke, 
despite its clear propensity to cause recurrent VTE23.
A published review of 388 patients with FD 
showed that 13% had suffered a stroke or TIA12. 
In our study, we found a similar percentage of events. 
The patients in our study had stroke with a mean age 
of 53.5 years while in the general population this event 
is more common after age 55, showing that Fabry 
patients are at risk of presenting this complication 
at an earlier age.
Although other studies have already reported a 
high incidence of thrombotic events in FD patients12,13 
with hereditary thrombophilia, this was not confirmed 
in our sample. Studies in larger cohorts and the 
evaluation of additional risk factors may be required 
to determine if any association exists.
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